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BrS

:   Brugada syndrome

CI

:   confidence interval

ECG

:   electrocardiogram

MAE

:   major arrhythmic events

NOS

:   Newcastle‐Ottawa quality assessment scale

RR

:   risk ratio

SCA

:   sudden cardiac arrest

SCD

:   sudden cardiac death

VF

:   ventricular fibrillation

VT

:   ventricular tachycardia

1. INTRODUCTION {#joa312290-sec-0005}
===============

Brugada syndrome (BrS) is an inherited arrhythmic disease associated with an increased risk of major arrhythmic events (MAE) and sudden cardiac death (SCD), and ventricular arrhythmias such as ventricular fibrillation (VF) and ventricular tachycardia (VT). It is characterized by a coved‐type ST elevation and atypical right bundle‐branch block appearances in the right precordial leads. The disease burden of BrS is difficult to determine; however, data suggest that the prevalence of asymptomatic patients with Brugada ECG pattern varies among different populations, ranging between 0% and 0.4%.[1](#joa312290-bib-0001){ref-type="ref"}, [2](#joa312290-bib-0002){ref-type="ref"}, [3](#joa312290-bib-0003){ref-type="ref"} With SCD being the most worrisome manifestation of BrS, identifying patients who would benefit from an implantable cardioverter‐defibrillator for primary prevention is critical; however, ventricular arrhythmia risk stratification remains challenging and controversial.

Many electrocardiogram (ECG) abnormalities have been proposed as markers for risk of MAE. Among them, conduction disturbances, such as delayed depolarization manifested as a wide QRS complex, may contribute to the development of MAE in BrS by providing or worsening a pro‐arrhythmic substrate.[4](#joa312290-bib-0004){ref-type="ref"} Previous studies reported that QRS duration may be useful as a predictor of MAE in BrS patients. Wide QRS complex, as defined by QRS duration \>120 milliseconds measured on a standard 12‐lead ECG, has been associated with an increased risk of ventricular arrhythmia.[5](#joa312290-bib-0005){ref-type="ref"} Additionally, wide QRS complex was also found to be more prominent in symptomatic BrS patients.[6](#joa312290-bib-0006){ref-type="ref"}, [7](#joa312290-bib-0007){ref-type="ref"} However, data from other studies reported conflicting results, suggesting that QRS width was not useful as a risk stratification tool.[8](#joa312290-bib-0008){ref-type="ref"}, [9](#joa312290-bib-0009){ref-type="ref"} Therefore, we aimed to assess whether wide QRS complex is associated with an increased risk of MAE in BrS patients by performing a systematic review and meta‐analysis.

2. METHOD {#joa312290-sec-0006}
=========

2.1. Search strategy {#joa312290-sec-0007}
--------------------

Two investigators (CK and NP) independently searched for published studies indexed in MEDLINE and EMBASE databases from inception to June 2019 using a search strategy that including the terms "ECG", "QRS", and "Brugada" as described in File [S1](#joa312290-sup-0001){ref-type="supplementary-material"}. Only full articles in English and studies conducted in cohorts were included. A manual search for additional pertinent studies and review articles using references from retrieved articles was also completed.

2.2. Inclusion criteria {#joa312290-sec-0008}
-----------------------

The eligibility criteria included the following: Cohort (prospective or retrospective), cross‐sectional, or randomized control trial studies reporting follow‐up outcome of MAE including SCD, sudden cardiac arrest (SCA), VF, sustained VT and appropriate shock in BrS patients with and without previously documented wide QRS complex as well as history of MAE as a characteristic.QRS duration, adjusted or unadjusted risk ratio (RR), odds ratio, hazard ratio with 95% confidence interval (CI), or sufficient raw data for the calculation were provided. Patients without previously documented wide QRS complex were used as controls. Odds ratio and hazard ratio were converted to RR by previously reported principal equations.[10](#joa312290-bib-0010){ref-type="ref"}

Study eligibility was independently determined by two investigators (RM and CT) and differences were resolved by mutual consensus. The Newcastle‐Ottawa quality assessment scale (NOS) was used to assess each study\'s quality in three domains, recruitment and selection of the participants, similarity and comparability between the groups, and ascertainment of the outcome of interest among cohort and case‐control studies.[11](#joa312290-bib-0011){ref-type="ref"}

2.3. Data extraction {#joa312290-sec-0009}
--------------------

A standardized data collection form was used to obtain the following information from each study: title of study, name of first author, year of publication, study design, country of origin, number, gender and age of the participants, Brugada ECG pattern, available MAE outcome, follow‐up duration, leads of QRS duration measurement, and confounders that were adjusted in the multivariable analysis, if available.

Two investigators (PP and PM) independently performed this data extraction process to ensure accurate data extraction. Any data discrepancy was resolved by referring back to the original articles.

2.4. Definition {#joa312290-sec-0010}
---------------

### 2.4.1. Wide QRS complex {#joa312290-sec-0011}

Wide QRS complex was defined as QRS complex with a duration of \>120 milliseconds.

### 2.4.2. Brugada syndrome {#joa312290-sec-0012}

Brugada syndrome was diagnosed in patients with ST‐segment elevation with type 1 morphology ≥2 mm in ≥1 lead in the right precordial leads V1, V2, positioned in the 2nd, 3rd, or 4th intercostal space occurring either spontaneously or after provocative drug test with intravenous administration of class I antiarrhythmic drugs.[12](#joa312290-bib-0012){ref-type="ref"}

### 2.4.3. Major arrhythmic event {#joa312290-sec-0013}

Major arrhythmic events were defined by either of SCD, SCA, VF, sustained VT, or appropriate shock. VF was defined as documented VF rhythm from standard 12‐lead ECG or Holter monitoring, or as defined in each study. Sustained ventricular tachycardia was defined as a sustained ventricular rhythm, documented from standard 12‐lead ECG or Holter monitoring, faster than 100 beats per minute lasting at least 30 seconds, or requiring termination earlier because of hemodynamic instability. Only sustained VT, VF, and appropriate defibrillator intervention were included in this study. Nonsustained VT and inappropriate shock were not considered an outcome of interest.

### 2.4.4. Sudden cardiac death and sudden cardiac arrest {#joa312290-sec-0014}

Sudden cardiac death was defined as an unexpected, nontraumatic death that occurred within 60 minutes from the onset of new or worsening symptoms or within 24 hours of last being observed alive.[13](#joa312290-bib-0013){ref-type="ref"} Sudden cardiac arrest was defined as a sudden cessation of cardiac activity with hemodynamic collapse for which an intervention or spontaneous reversion restores circulation.

2.5. Statistical analysis {#joa312290-sec-0015}
-------------------------

We performed a meta‐analysis of the included studies using a random‐effects model. Studies were excluded if they did not include an outcome in each intervention group or did not have enough information required for continuous data comparison. We pooled the point estimates of RR from each study using the generic inverse‐variance method of Der Simonian and Laird.[14](#joa312290-bib-0014){ref-type="ref"} To examine QRS duration, we calculated the weighted mean difference and 95% CIs of QRS duration between BrS patients with and without history of MAE. The heterogeneity of effect size estimates across these studies was quantified using the *I* ^2^ statistic. The *I* ^2^ statistic ranges in value from 0% to 100% (*I* ^2^ \< 25%, low heterogeneity; *I* ^2^ = 25%‐50%, moderate heterogeneity; and *I* ^2^ \> 50%, substantial heterogeneity).[15](#joa312290-bib-0015){ref-type="ref"} Publication bias was assessed using a funnel plot and the Egger\'s regression test[16](#joa312290-bib-0016){ref-type="ref"} (*P* \< .05 was considered significant). All data analyses were performed using the STATA SE version 14.2.

2.6. Sensitivity analysis {#joa312290-sec-0016}
-------------------------

A sensitivity analysis was performed to assess the influence of the individual studies on the overall results by omitting one study at a time. We used a sequential exclusion strategy, as described by Patsopoulos et al, to examine whether overall estimates were influenced by the substantial heterogeneity observed [17](#joa312290-bib-0017){ref-type="ref"}. We sequentially and cumulatively excluded studies that accounted for the largest share of heterogeneity until *I* ^2^ was less than 50%. We then examined whether RR estimates were consistent.

3. RESULT {#joa312290-sec-0017}
=========

3.1. Search results {#joa312290-sec-0018}
-------------------

Our search strategy yielded 872 potentially relevant articles (498 articles from EMBASE and 374 articles from MEDLINE). After the exclusion of duplicated articles, 456 articles underwent title and abstract review. At this stage, 360 articles were excluded as they were not cohort, case‐control, or randomized controlled trials, were not conducted in BrS patients, or the titles and abstracts were not relevant. This left 96 articles for full‐length review. A further 74 studies were excluded as they did not report data regarding QRS duration, reported QRS duration as continuous data, or did not provide sufficient data to calculate HR, RR, or OR. Therefore, a total of 22 studies were included in this meta‐analysis. Figure [1](#joa312290-fig-0001){ref-type="fig"} outlines the search and literature review process.

![Search methodology and selection process](JOA3-36-143-g001){#joa312290-fig-0001}

3.2. Description of included studies {#joa312290-sec-0019}
------------------------------------

A total of 22 studies from 2007 to 2018[6](#joa312290-bib-0006){ref-type="ref"}, [7](#joa312290-bib-0007){ref-type="ref"}, [9](#joa312290-bib-0009){ref-type="ref"}, [18](#joa312290-bib-0018){ref-type="ref"}, [19](#joa312290-bib-0019){ref-type="ref"}, [20](#joa312290-bib-0020){ref-type="ref"}, [21](#joa312290-bib-0021){ref-type="ref"}, [22](#joa312290-bib-0022){ref-type="ref"}, [23](#joa312290-bib-0023){ref-type="ref"}, [24](#joa312290-bib-0024){ref-type="ref"}, [25](#joa312290-bib-0025){ref-type="ref"}, [26](#joa312290-bib-0026){ref-type="ref"}, [27](#joa312290-bib-0027){ref-type="ref"}, [28](#joa312290-bib-0028){ref-type="ref"}, [29](#joa312290-bib-0029){ref-type="ref"}, [30](#joa312290-bib-0030){ref-type="ref"}, [31](#joa312290-bib-0031){ref-type="ref"}, [32](#joa312290-bib-0032){ref-type="ref"}, [33](#joa312290-bib-0033){ref-type="ref"}, [34](#joa312290-bib-0034){ref-type="ref"}, [35](#joa312290-bib-0035){ref-type="ref"}, [36](#joa312290-bib-0036){ref-type="ref"}, [37](#joa312290-bib-0037){ref-type="ref"} were included in our meta‐analysis involving 4,814 BrS patients. The mean age was 46.1 ± 12.8 years and patients were predominately men (77.6%) and Caucasian (67.1%). A summary of study characteristics is shown in Table [1](#joa312290-tbl-0001){ref-type="table"}. Among 22 included studies, 16 studies[6](#joa312290-bib-0006){ref-type="ref"}, [18](#joa312290-bib-0018){ref-type="ref"}, [19](#joa312290-bib-0019){ref-type="ref"}, [21](#joa312290-bib-0021){ref-type="ref"}, [22](#joa312290-bib-0022){ref-type="ref"}, [24](#joa312290-bib-0024){ref-type="ref"}, [26](#joa312290-bib-0026){ref-type="ref"}, [28](#joa312290-bib-0028){ref-type="ref"}, [29](#joa312290-bib-0029){ref-type="ref"}, [30](#joa312290-bib-0030){ref-type="ref"}, [31](#joa312290-bib-0031){ref-type="ref"}, [32](#joa312290-bib-0032){ref-type="ref"}, [33](#joa312290-bib-0033){ref-type="ref"}, [34](#joa312290-bib-0034){ref-type="ref"}, [35](#joa312290-bib-0035){ref-type="ref"}, [36](#joa312290-bib-0036){ref-type="ref"} reported mean QRS duration compared between BrS with and without history of MAE and 7 studies[7](#joa312290-bib-0007){ref-type="ref"}, [9](#joa312290-bib-0009){ref-type="ref"}, [18](#joa312290-bib-0018){ref-type="ref"}, [20](#joa312290-bib-0020){ref-type="ref"}, [23](#joa312290-bib-0023){ref-type="ref"}, [25](#joa312290-bib-0025){ref-type="ref"}, [27](#joa312290-bib-0027){ref-type="ref"} reported the incidence, odds ratio, hazard ratio, or RR of MAE during follow‐up period compared between BrS with wide (\>120 milliseconds) and normal QRS duration (≤120 milliseconds).

###### 

Summary characteristics of individual included studies of patients with a Brugada syndrome

  Study (year)                Study design                 N      Country                                       Men (%)   Mean age (years)   Symptomatic BrS (%)   Follow‐up (months)   Factors adjusted in analyses      Leads measured   Outcomes
  --------------------------- ---------------------------- ------ --------------------------------------------- --------- ------------------ --------------------- -------------------- --------------------------------- ---------------- -------------------------------
  de Asmundis et al, (2017)   Cohort                       289    Belgium                                       70.2      44.8 ± 16.0        35.6                  120.6 ± 55.7         N/A                               V1‐V3            SCD or appropriate shcok
  Benito et al (2008)         Cohort                       384    Spain, Belgium, and Canada                    70.8      45.9 ± 15.3        21.6                  57.9 ± 48.8          N/A                               V2               VF or SCD
  Calò et al (2016)           Prospective cohort           347    Italy                                         78.4      45.0 ± 13.1        20.5                  48.0 ± 38.6          N/A                               V2               VF or SCD
  Conte et al (2013)          Retrospective cohort         503    Belgium                                       58        40.7 ± 12.3        46                    29 ± 8               N/A                               V1‐V2            sVT or VF
  Furushima et al (2005)      Case‐control                 24     Japan                                         95.8      60.0 ± 14.4        62.5                  33 ± 16              N/A                               V1‐V2            SCA
  Ikeda et al (2005)          Prospective cohort           124    Japan                                         94.4      50.0 ± 15.0        33.1                  40.0 ± 19.0          N/A                                                sVT, VF, or SCD
  Junttila et al (2008)       Case‐control                 200    Findland, Belgium, China, Spain, and Canada   71.20     40 ± 16            33                    N/A                  Gender, age, and SCN5A mutation                    sVT, VF, or SCD
  Kanda et al (2012)          Retrospective cohort         34     Japan                                         97.1      43.5 ± 12.4        100                   38                   N/A                               V5‐V6            VF or SCA
  Kawata et al (2013)         Prospective cohort           49     Japan                                         94        46.0 ± 12.7        35                    93.8 ± 45.6          N/A                               N/A              VF or SCD
  Kawazoe et al (2016)        Case‐control                 143    Japan                                         97.9      46.17 ± 12.7       32.9                  82.8 ± 49.0          N/A                               V6               VF
  Makarawate et al (2017)     Prospective cohort           40     Thailand                                      97.5      43.5 ± 12.7        100                   28.3 ± 11.3          N/A                               N/A              Appropriate shock
  Morita et al (2018)         Case‐control                 62     Japan                                         100       50.1 ± 10.9        22.6                  27‐134               N/A                               V3               VF
  Nakano et al (2010)         Prospective cohort           52     Japan                                         94.2      42 ± 3             34.6                  39 + 4               NA                                V1‐V2            VF
  Nishii et al (2010)         Prospective cohort           108    Japan                                         97.2      46.8 ± 11.6        38.9                  71.9 ± 41.3          N/A                               V5               VF
  Park et al (2003)                                        15     Korea                                         86.7      44 ± 10            87                    19 ± 14              N/A                               N/A              VF
  Probst et al (2010)         Prospective cohort           1029   Italy, Germany, France and The Netherlands    72        45 ± 5             36                    40 ± 50              N/A                               N/A              SCA
  Sieira et al (2017)         Retrospective cohort         400    Belgium                                       58.3      41.1 ± 17.8        32.7                  80.7 ± 57.2          N/A                               N/A              SCD
  Takagi et al (2007)         Retrospective cohort         188    Japan                                         94.7      53 ± 14            47.9                  37 ± 16              N/A                               V6               VF
  Take et al (2012)           Retrospective cohort         84     Japan                                         97.6      47 ± 12            48.8                  48 ± 48              N/A                               SAEG             VF
  Tokioka et al (2014)        Prospective cohort           246    Japan                                         95.9      47.6 ± 13.6        N/A                   45.1 ± 44.3          N/A                               V2               SCD, VF
  Yamagata et al (2017)       Prospective cohort           415    Japan                                         97        46 ± 14            45.3                  72                   N/A                               V2               Appropriate shock, SCA or SCD
  Zumhagen et al (2016)       Retrospective cros‐section   78     Germany                                       73.1      45 + 14            65.4                  N/A                  N/A                               V1               sVT, VF, or SCD

Abbreviations: N/A, not applicable; SCA, sudden cardiac arrest; SCD, sudden cardiac death; sVT, sustained ventricular tachycardia; VF, ventricular fibrillation.
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### 3.2.1. Quality assessment of included studies {#joa312290-sec-0020}

The NOS of included studies are described in File [S2](#joa312290-sup-0002){ref-type="supplementary-material"}. The NOS uses a star system (0 to 9) to evaluate included studies on 3 domains: selection, comparability, and outcomes. Higher scores represent a higher study quality.

3.3. Meta‐analysis results {#joa312290-sec-0021}
--------------------------

### 3.3.1. Wide QRS complex and major arrhythmic event {#joa312290-sec-0022}

Outcomes regarding MAE were available in 7 studies.[7](#joa312290-bib-0007){ref-type="ref"}, [9](#joa312290-bib-0009){ref-type="ref"}, [18](#joa312290-bib-0018){ref-type="ref"}, [20](#joa312290-bib-0020){ref-type="ref"}, [23](#joa312290-bib-0023){ref-type="ref"}, [25](#joa312290-bib-0025){ref-type="ref"}, [27](#joa312290-bib-0027){ref-type="ref"} There was a significant association between wide QRS complex and an increased risk of MAE (pooled RR = 1.55, 95% CI: 1.04‐2.30, *P* = .03, *I* ^2^ = 38.4%). QRS duration was wider in BrS who had history of MAE (weight mean difference = 8.12 milliseconds, 95% confidence interval: 5.75‐10.51 milliseconds, *I* ^2^ = 43.4%). Forest plot is demonstrated in Figures [2](#joa312290-fig-0002){ref-type="fig"} and [3](#joa312290-fig-0003){ref-type="fig"}, respectively.

![Forest plot demonstrating the association of wide QRS and MAE in patients with Brugada syndrome](JOA3-36-143-g002){#joa312290-fig-0002}

![Forest plot demonstrating weight mean difference QRS duration between Brugada syndrome patient with and without history of MAE](JOA3-36-143-g003){#joa312290-fig-0003}

### 3.3.2. Sensitivity analysis {#joa312290-sec-0023}

To assess the stability of the results of the meta‐analysis, we conducted a sensitivity analysis for each outcome by excluding one study at a time. When omitting Calo et al[18](#joa312290-bib-0018){ref-type="ref"}, Junttika et al[7](#joa312290-bib-0007){ref-type="ref"}, Tokioka et al[9](#joa312290-bib-0009){ref-type="ref"}, or Yamagata et al[20](#joa312290-bib-0020){ref-type="ref"}, wide QRS still increased MAE (RR = 1.49, 1.39, 1.40, and 1.57 respectively) but the results were nonsignificant (File [S3](#joa312290-sup-0003){ref-type="supplementary-material"}).

### 3.3.3. Publication bias {#joa312290-sec-0024}

We aimed to investigate potential publication bias via funnel plot and Egger\'s test. No publication bias was observed in Egger\'s test (*P* = .051 for QRS duration weight mean difference analysis and *P* = .500 for wide QRS analysis) or funnel plot (Figures [4](#joa312290-fig-0004){ref-type="fig"} and [5](#joa312290-fig-0005){ref-type="fig"}).[38](#joa312290-bib-0038){ref-type="ref"}, [39](#joa312290-bib-0039){ref-type="ref"}

![Funnel plot of the association of wide QRS and MAE in patients with Brugada syndrome](JOA3-36-143-g004){#joa312290-fig-0004}

![Funnel plot of weight mean difference QRS duration between Brugada syndrome patient with and without history of MAE](JOA3-36-143-g005){#joa312290-fig-0005}

4. DISCUSSION {#joa312290-sec-0025}
=============

The main finding from this meta‐analysis is that the wide QRS complex on surface 12‐lead ECG is associated with an increased risk of MAE in patients with BrS.

Brugada syndrome has been reported to be responsible for up to 20% of SCD in patients with a structurally normal heart, and likely the cause in 4% of all SCD.[40](#joa312290-bib-0040){ref-type="ref"} Placement of ICD is a class I recommendation in BrS patients with a previous history of MAE, including SCD, SCA, VF, or sustained VT[41](#joa312290-bib-0041){ref-type="ref"}, [42](#joa312290-bib-0042){ref-type="ref"} However, a majority of newly diagnosed BrS patients are without previous history of MAE, and thus, they may not meet an indication for ICD placement.[43](#joa312290-bib-0043){ref-type="ref"} In addition, it remains a challenge to identify asymptomatic patients who are at risk of MAE.[41](#joa312290-bib-0041){ref-type="ref"}

From the current evidence, the only well‐established risk factor for MAE in BrS population is spontaneous type I ECG pattern with a presence of symptoms (previous MAE or syncope presumed to be due ventricular arrhythmias).[42](#joa312290-bib-0042){ref-type="ref"} This pattern is more commonly found in adult male, Asians ethnicity, and patients with fever.[44](#joa312290-bib-0044){ref-type="ref"} Other factors that are associated with increased risk of MAE include male gender, proband status, family history of SCD, early repolarization, fragmented QRS, atrial fibrillation, prolonged atrio‐His and His‐ventricular intervals, and inducible ventricular arrhythmia during the electrophysiological study.[6](#joa312290-bib-0006){ref-type="ref"}, [18](#joa312290-bib-0018){ref-type="ref"}, [21](#joa312290-bib-0021){ref-type="ref"}, [45](#joa312290-bib-0045){ref-type="ref"}, [46](#joa312290-bib-0046){ref-type="ref"}, [47](#joa312290-bib-0047){ref-type="ref"}, [48](#joa312290-bib-0048){ref-type="ref"}, [49](#joa312290-bib-0049){ref-type="ref"}, [50](#joa312290-bib-0050){ref-type="ref"}, [51](#joa312290-bib-0051){ref-type="ref"}, [52](#joa312290-bib-0052){ref-type="ref"}, [53](#joa312290-bib-0053){ref-type="ref"}, [54](#joa312290-bib-0054){ref-type="ref"} To the first of the authors\' knowledge, this is the first systematic review and meta‐analysis to evaluate the association between wide QRS complex and risk of MAE in BrS population.

There are three well‐known suggested mechanisms that could explain the ventricular arrhythmia in BrS,[55](#joa312290-bib-0055){ref-type="ref"} including the repolarization, the depolarization, microscopic fibrosis, myocyte inflammation, and the neural crest models, which are all originated from the right ventricular outflow tract abnormality found in BrS patients.[56](#joa312290-bib-0056){ref-type="ref"}, [57](#joa312290-bib-0057){ref-type="ref"}, [58](#joa312290-bib-0058){ref-type="ref"}, [59](#joa312290-bib-0059){ref-type="ref"} However, experts believe that there may be other involving factors, yet to be discovered, that also play major role in MAE in BrS patients. Mutation of the SCN5A gene, which encodes the pore‐forming region of the cardiac sodium channel, is the most common gene mutation found in BrS patients, with the impaired sodium channels predisposing patients to phase 2 reentry precipitating ventricular arrhythmias.[6](#joa312290-bib-0006){ref-type="ref"}, [47](#joa312290-bib-0047){ref-type="ref"} However, this mutation was only found in less than 30% of the patients with BrS[55](#joa312290-bib-0055){ref-type="ref"}, [60](#joa312290-bib-0060){ref-type="ref"} and only shown to be associated with MAE in Asian populations but not Caucasian populations.[20](#joa312290-bib-0020){ref-type="ref"}, [50](#joa312290-bib-0050){ref-type="ref"} Most patients with BrS do not have an identifiable mutation. This indicates that there are likely still other causal genes that are yet to be found or other factors not yet described.

A wide QRS complex is a previously described feature shown in the surface ECG of BrS pattern. This conduction abnormality is the likely result of the decreased function of the sodium channel and the abnormal sodium current influx found in an individual with SCN5A gene mutation, leading to lethal arrhythmias in BrS.[4](#joa312290-bib-0004){ref-type="ref"}, [61](#joa312290-bib-0061){ref-type="ref"} Ohkubo et al reported that QRS duration \>120 milliseconds in lead V2 can be used as a predictor of ventricular arrhythmias in BrS population.[5](#joa312290-bib-0005){ref-type="ref"} Smits et al found that BrS patients with the SCN5A mutation showed a trend toward longer QRS duration in lead V2, with prolongation of both atrio‐His and His‐Ventricular (HV) interval, compared with the BrS patients without SCN5A mutation.[62](#joa312290-bib-0062){ref-type="ref"} In addition, Bordachar et al also revealed that patients with an HV interval \>55 milliseconds had significantly more atrial arrhythmias than those with a normal HV interval, which subsequently predispose such patients to MAE. The etiology is unclear but could be from L‐type calcium channel mutation or microscopic fibrosis.

Nevertheless, it is important to note that BrS is a heterogeneous disease, meaning that the mechanism of MAE could differ in each patient. Wide QRS is not the only depolarization ECG marker for the increased risk of MAE, as fragmented QRS, QRS dispersion, and presence of late potentials have also been described.[52](#joa312290-bib-0052){ref-type="ref"}, [63](#joa312290-bib-0063){ref-type="ref"} Tse et al reported higher QRS dispersion in Type‐1 BrS than non‐Type‐1 BrS. However, no MAE was compared or reported.[64](#joa312290-bib-0064){ref-type="ref"} Our group published a comprehensive systemic review and meta‐analysis on fragmented QRS as a predictor of arrhythmic event in BrS and showed that baseline fragmented QRS increased major arrhythmic events up to 3‐fold.[52](#joa312290-bib-0052){ref-type="ref"} Repolarization markers, such as early repolarization and prolonged QT interval, have also been associated with MAE risk.[9](#joa312290-bib-0009){ref-type="ref"}, [65](#joa312290-bib-0065){ref-type="ref"}, [66](#joa312290-bib-0066){ref-type="ref"}, [67](#joa312290-bib-0067){ref-type="ref"} While a wide QRS complex may have a direct effect to MAE development in certain patients, in other patients this finding is just a sign of a more advanced disease.

4.1. Limitations {#joa312290-sec-0026}
----------------

Our study is not without limitations. We observed moderate heterogeneity (*I* ^2^ = 38.4 and 43.4%) likely because of different patient characteristics, univariate analysis, and measurement leads. The unadjusted studies may be influenced by other confounders causing instability of the result observed in sensitivity analysis. Lastly, despite the association between wide QRS complex and MAE in BrS population, causality cannot be concluded from our study.

5. CONCLUSION {#joa312290-sec-0027}
=============

Our systematic review and meta‐analysis demonstrate that the presence of wide QRS complex on the 12‐lead ECG is associated with an increased risk of MAE in patients with BrS. This marker can be easily obtained on the surface ECG and can be used to help stratify the risk for MAE in this population.
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